Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Current Opinion in HIV and AIDS Pub Date : 2022-07-01 DOI:10.1097/COH.0000000000000742

Seemal F Awan, Myra Happe, Amelia R Hofstetter, Lucio Gama

{"title":"Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.","authors":"Seemal F Awan, Myra Happe, Amelia R Hofstetter, Lucio Gama","doi":"10.1097/COH.0000000000000742","DOIUrl":null,"url":null,"abstract":"Purpose of review: Anti-HIV-1 broadly neutralizing antibodies (bNAbs) are promising agents in the fight against the AIDS epidemic. Multiple bNAbs have been already evaluated in clinical trials with encouraging results. This review discusses the use of bNAbs for the prevention and treatment of HIV-1 infection, focusing on manufactured products that have been evaluated in clinical settings.Recent findings: More than 17 bNAbs have been evaluated for safety and pharmacokinetics in humans. The vast majority presented a well tolerated profile and were generally well tolerated. Serum half-life varied from 12 to 73.5 days and can be improved by the addition of mutations to the Fc regions. Results from the antibody-mediated prevention (AMP) study show that VRC01, a CD4-binding-site bNAb, was effective at preventing the acquisition of sensitive HIV-1 strains but did not prevent the acquisition of strains whose in vitro sensitivity to the antibody had an IC80 of more than 1 μg/ml. New bNAb combinations to improve coverage are currently being evaluated.Summary: In this review, we discuss the current landscape of HIV-1 bNAbs in clinical development. We also present the current strategies employed to improve the breadth, potency, serum half-life, effector function and administration of these compounds.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":" ","pages":"247-257"},"PeriodicalIF":4.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in HIV and AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000742","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Purpose of review: Anti-HIV-1 broadly neutralizing antibodies (bNAbs) are promising agents in the fight against the AIDS epidemic. Multiple bNAbs have been already evaluated in clinical trials with encouraging results. This review discusses the use of bNAbs for the prevention and treatment of HIV-1 infection, focusing on manufactured products that have been evaluated in clinical settings.

Recent findings: More than 17 bNAbs have been evaluated for safety and pharmacokinetics in humans. The vast majority presented a well tolerated profile and were generally well tolerated. Serum half-life varied from 12 to 73.5 days and can be improved by the addition of mutations to the Fc regions. Results from the antibody-mediated prevention (AMP) study show that VRC01, a CD4-binding-site bNAb, was effective at preventing the acquisition of sensitive HIV-1 strains but did not prevent the acquisition of strains whose in vitro sensitivity to the antibody had an IC80 of more than 1 μg/ml. New bNAb combinations to improve coverage are currently being evaluated.

Summary: In this review, we discuss the current landscape of HIV-1 bNAbs in clinical development. We also present the current strategies employed to improve the breadth, potency, serum half-life, effector function and administration of these compounds.

查看原文本刊更多论文

广泛中和抗体用于治疗和预防HIV-1感染。

综述目的:抗hiv -1广泛中和抗体(bNAbs)是对抗艾滋病流行的有前途的药物。多种bnab已经在临床试验中获得了令人鼓舞的结果。这篇综述讨论了bnab在预防和治疗HIV-1感染中的应用，重点是已在临床环境中进行评估的制成品。最近的发现:超过17种bnab在人体的安全性和药代动力学方面进行了评估。绝大多数表现出良好的耐受性，并且通常耐受性良好。血清半衰期从12天到73.5天不等，可以通过在Fc区添加突变来改善。抗体介导的预防(AMP)研究结果表明，cd4结合位点bNAb VRC01能有效阻止HIV-1敏感株的获得，但不能阻止对该抗体体外敏感性大于1 μg/ml的株的获得。目前正在评估新的bNAb组合以提高覆盖率。摘要:在这篇综述中，我们讨论了HIV-1 bNAbs在临床开发中的现状。我们还提出了目前用于改善这些化合物的广度、效力、血清半衰期、效应功能和给药的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

7.30%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.